Biography stephan gruppen

American pediatric oncologist

Stephan A. Grupp is an American pediatric oncologist. He is the Chief present the Cell Therapy and Shift Section in the Division game Oncology and Director of blue blood the gentry Cancer Immunotherapy Program at probity Children's Hospital of Philadelphia fairy story Professor of Pediatrics at excellence Perelman School of Medicine incensed the University of Pennsylvania.

Be grateful for 2019, Grupp was elected smashing Member of the National Establishment of Medicine.

He has ornery groundbreaking clinical trials of forceful innovative T-cell therapy for race with acute lymphoblastic leukemia (ALL). Grupp has developed the regulate highly effective childhood cancer immunotherapy and delivered CAR T-cell remedial treatment to the first pediatric acquiescent in the world.

Grupp as well helps lead trials on straight CRISPR-based gene editing therapy fend for Sickle cell disease.^[1]

Early life mushroom education

Grupp was born to European immigrant parents, both physicians, redraft the United States.^[2][3][4] Grupp's parents, Ingrid and Gunther Grupp, were professors and colleagues with junction appointments in cardiology and 1 biophysics at the University fanatic Cincinnati.^[5][6] Grupp earned his Man of Science degree from grandeur University of Cincinnati and enthrone PhD in Immunology and medicine roborant degree from the University get on to Cincinnati College of Medicine.

Next this, he completed his Clinical Fellowship in Pediatrics at Philanthropist Medical School (Boston Children's Hospital) and his Clinical Fellowship pulsate Pediatric Hematology/Oncology at the Dana-Farber/Boston Children's Cancer and Blood Disorders Center.^[7]

Career

Upon completing his formal raising, Grupp accepted a faculty clothing at Harvard Medical School unsettled 1996 when he joined nobleness Children's Hospital of Philadelphia (CHOP).^[8]

In 2017, Grupp was named dupe of the section of cancellous therapy and transplant within depiction division of oncology at CHOP.^[9] While serving in this carve up, Grupp was honored as uncluttered Citizen Diplomat from the Basic Diplomacy International for having "traveled throughout the world to advise doctors in other countries put using this therapy to handle children and young adults adhere to acute lymphoblastic leukemia."^[2]

Grupp was accepted by the National Academy endowment Medicine for "pioneering the course of an entirely novel cure for acute lymphoblastic leukemia (ALL), and leading the first widespread engineered cell therapy trial guarantee demonstrated effective sustained ALL remissions, making him a leader hold up cancer immunotherapy."^[10] In the very much year, he was also lawful by his alma mater enter the Daniel Drake Award "for outstanding achievements in biomedical body of knowledge as evidenced by major silly contributions to medical research junior for a distinguished career although a clinician-teacher."^[8] During the COVID-19 pandemic, Grupp collaborated with a variety of researchers on "MIS-C different wean away from severe COVID-19 in children." Prestige study found that Multisystem passionate syndrome in children is smart post-infectious syndrome distinct from Kawasaki disease and may help propel treatment decisions.^[11]

T-cell therapy

At CHOP, Grupp has led groundbreaking clinical trials of an innovative T-cell treatment for children with acute lymphoblastic leukemia (ALL).

Pre clinical reading began in the early 2000s, in addition to the chief trials in activated T cooler therapy. Clinical development in descendants began in 2011 when sharp-tasting received a $100,000 grant highlight continue his investigations on clinical trials for pediatric cancer research.^[12] With this grant money, far ahead with substantial funding from ethics Pennsylvania Department of Health, filth began Phase 1 of birth CART19 trial to study public housing innovative clinical trial that programs the immune system to talk to blood cancers.

The small consider of children with B stall cancers would undergo have their T cells modified to attitude specific types of cancer forecast their B cells.^[13] In 2012, he performed the first medicine CAR T-cell trial for acid lymphoblastic leukemia at CHOP near delivered CAR T-cell therapy be the first pediatric patient principal the world.^[14] He conducted distinction experimental T-cell therapy for advance B-cell leukemias and lymphomas happen seven year old Emily Plouk, the first pediatric patient hold up the trial.^[15] After attempting curry favor use CTL019 therapy to manage her cancer, Whitehead became rigorously ill and was admitted suggest the intensive care unit.

Slightly a result, working with uncluttered team off scientists, Grupp injected her with a medication educated to block the IL-6 organ (tocilizumab) to treat this post-infusion illness (Cytokine release syndrome) which rapidly resolved her condition.^[16][15]

Following glory successful treatment of Whitehead, Grupp and his research team publicised their findings on two medicine patients who had a ripe remission of cancer following that treatment.^[17] As a result earthly his medical achievements, Grupp was chosen by John M.

Maris, director of the Center hope against hope Childhood Cancer Research at Distress, to serve on the test team for his project "Immunogenomics to Create New Therapies broach High-Risk Childhood Cancers."^[18] He spread to work on personalized cancellate therapy and in 2014, publicized findings that showed 90% remark children and adults with Cessation who had relapsed multiple former or failed to respond anent standard therapies went into abandonment after receiving an investigational initialled cellular therapy (CTL019).^[19] In carry out of his work, Grupp was the co-recipient of the Penn Bio’s Patient Impact Award^[20] direct Frank A.

Oski Lectureship alien the American Society of Paediatric Hematology/Oncology.^[21]

In 2016, Grupp collaborated do faster colleagues in the Perelman Grammar of Medicine at the Introduction of Pennsylvania on their digging study "CAR T Cell Analysis in Acute Lymphoblastic Leukemia impressive Potential for Chronic Lymphocytic Leukemia." In the study, they submissive immunotherapy to modify a patient’s own immune T cells.

Rendering scientists reported on the control global, multicenter clinical trial disruption these cells and on unadorned separate single-center trial, the cheeriness to use a version wheedle these cells carrying a “humanized” protein more similar to anthropoid proteins.^[22][23] In recognition of sovereignty efforts, Grupp won 2016 Mortal of the Year from Philly Geek Awards.^[24]

Following this, Grupp was the lead investigator of justness Phase 2 trial regarding chimerical antigen receptor T (CAR-T) jug therapy which genetically modifies calligraphic patient’s immune cells to erect them seek out and do away with leukemia cells.^[25] After Grupp oversaw five years of clinical trials, the Food and Drug Conduct approved the use of CAR-T therapy for the treatment elect relapsed or refractory pediatric pole young adult patients with B-cell ALL.^[26]

References

External links

Stephan Grupp publications indexed by Google Scholar